试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid TumorsCTIS2023-509867-26-00Eli Lilly & Co.112
招募中
1 期
A Phase 1a/b study of LOXO-435 in Advanced Solid Tumor Malignancies with FGFR3 AlterationsAdvanced Solid Tumor Malignancies with FGFR3 AlterationsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2022-502755-59-00Eli Lilly & Co.200
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.CTIS2024-513106-62-00Sun Pharmaceutical Industries Limited30
进行中（未招募）
1 期
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001Chronic Hepatitis BCTIS2023-504288-18-00Zhejiang Yaoyuan Biotechnology Co. Ltd.119
招募中
1 期
A study to learn if UCB3101 is safe and how it moves through the body of healthy participantsHealthy ParticipantsMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848CTIS2023-504586-24-00CB Biopharma88